The sphere-forming ability of SERBP1-knockout GBM cells decreases by 60%, the sensitivity to temozolomide (TMZ) increases by 2.5 times, and the tumor growth rate in nude mouse xenograft models decreases by 58%, confirming that SERBP1 is a key regulatory factor for the malignant phenotype of GBM [3,32]. The gene discussed is SERBP1; the disease is glioblastoma.